CG
TGTX icon

Cutler Group’s TG Therapeutics TGTX Stock Holding History

Cutler Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,100
Closed -$10K – 3571
2023
Q4 		$10K Hold
3,100
– – ﹤0.01% 2410
2023
Q3 		$36K Buy
+3,100
New +$43.2K ﹤0.01% 1679
2023
Q1 		– Sell
-13,000
Closed -$4K – 4708
2022
Q4 		$4K Buy
13,000
+12,900
+12,900% +$93.6K ﹤0.01% 3366
2022
Q3 		$1K Sell
100
-3,000
-97% -$19.7K ﹤0.01% 4703
2022
Q2 		$6K Sell
3,100
-5,600
-64% -$35K ﹤0.01% 3623
2022
Q1 		$39K Buy
8,700
+4,500
+107% +$52.1K ﹤0.01% 2467
2021
Q4 		$31K Sell
4,200
-900
-18% -$23.4K ﹤0.01% 2775
2021
Q3 		$17K Hold
5,100
– – ﹤0.01% 3505
2021
Q2 		$18K Buy
5,100
+2,700
+113% +$106K ﹤0.01% 3408
2021
Q1 		$11K Sell
2,400
-7,200
-75% -$346K ﹤0.01% 3746
2020
Q4 		$12K Buy
9,600
+4,600
+92% +$155K ﹤0.01% 3076
2020
Q3 		$10K Sell
5,000
-2,500
-33% -$57.5K ﹤0.01% 3015
2020
Q2 		$13K Buy
+7,500
New +$121K ﹤0.01% 2696
2019
Q1 		– Sell
-2,000
Closed -$2K – 4746
2018
Q4 		$2K Sell
2,000
-7,700
-79% -$38.3K ﹤0.01% 3441
2018
Q3 		$42K Buy
+9,700
New +$111K ﹤0.01% 1722
2018
Q1 		– Sell
-1,300
Closed -$1K – 5195
2017
Q4 		$1K Sell
1,300
-800
-38% -$6.99K ﹤0.01% 4578
2017
Q3 		$1K Sell
2,100
-4,400
-68% -$50.1K ﹤0.01% 5564
2017
Q2 		$5K Sell
6,500
-53,700
-89% -$601K ﹤0.01% 4872
2017
Q1 		$28K Buy
+60,200
New +$432K ﹤0.01% 2991
2016
Q2 		– Sell
-14,500
Closed -$161K – 7282
2016
Q1 		$161K Buy
14,500
+200
+1% +$1.75K 0.01% 1170
2015
Q4 		$120K Buy
+14,300
New +$181K 0.01% 1607

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's TGTX Position: Q1 2024 in Review

Cutler Group sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 2,080 shares — an estimated $33.1K sold.

Cutler Group first reported a position in TGTX in Q4 2015 and held it in 26 quarters. The position peaked at $141K in Q3 2021. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Cutler Group reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 2,080 TG Therapeutics shares in Q1 2024, an estimated $33.1K.
  • Cutler Group first reported a position in TG Therapeutics in Q4 2015 and held it in 26 quarters.
  • Cutler Group's TG Therapeutics position peaked at $141K in Q3 2021.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.